BlackRock Institutional Trust’s Juno Therapeutics, Inc. JUNO Stock Holding History

BlackRock Institutional Trust’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$34.5M	Buy	1,830,981 +73,231	+4%	+$1.79M	0.01%	1573
2016 Q3	$52.8M	Buy	1,757,750 +94,570	+6%	+$2.94M	0.01%	1266
2016 Q2	$63.9M	Buy	1,663,180 +475,709	+40%	+$19.7M	0.01%	1088
2016 Q1	$45.2M	Sell	1,187,471 -13,266	-1%	-$462K	0.01%	1287
2015 Q4	$52.8M	Buy	1,200,737 +116,278	+11%	+$5.77M	0.01%	1202
2015 Q3	$44.1M	Buy	1,084,459 +661,366	+156%	+$29M	0.01%	1299
2015 Q2	$22.6M	Buy	423,093 +11,923	+3%	+$633K	﹤0.01%	1840
2015 Q1	$24.9M	Buy	411,170 +408,256	+14,010%	+$19.8M	﹤0.01%	1801
2014 Q4	$152K	Buy	+2,914	New	+$130K	﹤0.01%	3678

Other funds holding JUNO

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

BlackRock Institutional Trust's JUNO Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Juno Therapeutics, Inc. (JUNO) stake by 4.2% in Q4 2016, buying an estimated $1.79M and bringing the position to 1,830,981 shares worth $34.5M. The position accounts for 0.01% of the portfolio, ranked #1573.

BlackRock Institutional Trust first reported a position in JUNO in Q4 2014 and has held it in 9 quarters since. The position peaked at $63.9M in Q2 2016. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

BlackRock Institutional Trust held 1,830,981 shares of Juno Therapeutics, Inc. worth $34.5M as of Q4 2016.
BlackRock Institutional Trust bought 73,231 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $1.79M.
Juno Therapeutics, Inc. made up 0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #1573 holding.
BlackRock Institutional Trust first reported a position in Juno Therapeutics, Inc. in Q4 2014 and has held it in 9 quarters since.
BlackRock Institutional Trust's Juno Therapeutics, Inc. position peaked at $63.9M in Q2 2016.
159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.